Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Centanafadine Pharmacodynamic Interaction With Stimulants in Healthy Adults
NCT07314333Phase 1Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Feb 2026
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of centanafadine in attention deficit hyperactivity disorder (ADHD) (6 arms), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoints: Change from Baseline in Blood Pressure at Day 12 and Change from Baseline in Heart Rate at Day 12. Started Feb 2026; status: completed.
02
Drugs
centanafadine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT07314333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07314333.